Description
Summary Abstract
Phenibut (β-phenyl-γ-aminobutyric acid HCl; PhGABA; CAS 1078-21-3) is a synthetic GABA analogue developed in the Soviet Union in the 1960s and approved clinically in Russia for anxiolytic, nootropic, and sedative-hypnotic indications. It incorporates a phenyl ring at the β-carbon of GABA, substantially increasing blood-brain barrier permeability relative to native GABA. Phenibut exerts its primary pharmacological effects through (R)-enantioselective agonism at GABAB receptors and concurrent blockade of the α2δ subunit of voltage-dependent calcium channels (VDCCs), mirroring the gabapentinoid mechanism of gabapentin and pregabalin. Secondary dopaminergic activation at low doses contributes to its unique nootropic profile, distinguishing it from classical GABAB agonists such as baclofen.
Clinical Indications
Published research and clinical use in Eastern Europe spans several neuropsychiatric and pain contexts:
- Anxiety and stress: Phenibut has been used clinically in Russia for decades as an anxiolytic and antistress agent; preclinical and clinical data support GABAB-mediated reduction of conditioned fear, tension, and psychosomatic anxiety without the full sedation profile of benzodiazepines.
- Neuropathic pain: Via α2δ VDCC blockade analogous to gabapentin, phenibut attenuates allodynia and hyperalgesia in chronic pain models; R-phenibut’s antinociceptive effects are blocked by α2δ antagonists but not by GABAB antagonists.
- Cognitive and nootropic research: At low doses phenibut facilitates conditioned reflex formation in passive avoidance paradigms and improves rotarod performance in rodents, consistent with a selective nootropic component distinct from sedation.
Contraindications
- Dependence and withdrawal risk: Chronic high-dose phenibut administration leads to receptor supersensitization; abrupt discontinuation produces a withdrawal syndrome including anxiety, agitation, and autonomic instability — important in repeated-dose study designs.
- CNS depressant combinations: Phenibut potentiates the central effects of barbiturates, anesthetics, and alcohol; concurrent CNS depressant exposure must be controlled in experimental designs.
- Cardiovascular sensitivity: At overdose concentrations, phenibut can produce QRS complex prolongation via VDCC blockade; high-dose models require cardiac monitoring.
Mechanism of Action (MOA)
Phenibut’s pharmacological profile derives from its stereoselective dual receptor engagement and BBB-permeable GABA-mimetic structure:
GABAB Receptor Agonism
The (R)-enantiomer of phenibut selectively binds GABAB metabotropic G-protein–coupled receptors (Ki ≈ 92 μM for racemic; ~30-fold lower affinity than baclofen). GABAB activation reduces intracellular cAMP, opens K+ channels, and inhibits voltage-gated Ca2+ entry, producing slow inhibitory postsynaptic potentials underlying anxiolytic and sedative effects.
α2δ Subunit VDCC Blockade
Both R- and S-enantiomers bind the α2δ subunit of voltage-dependent calcium channels with higher affinity (Ki ≈ 23–60 μM) than their GABAB affinity — identifying gabapentinoid activity as a primary pharmacological target. This mechanism mediates antinociceptive and anti-allodynic effects independent of GABAB engagement.
Dopaminergic Modulation
At lower doses, phenibut increases striatal dopamine and its metabolites (homovanillic and 3,4-dihydroxyphenylacetic acids) and antagonizes β-phenylethylamine (PEA), a proposed endogenous anxiogen. This dopaminergic activation contributes to the nootropic, “day-tranquilizer” character of phenibut and its thymoleptic (mood-elevating) component.
Neuronal Excitability Modulation
Phenibut increases the inhibitory GABA neurotransmitter tone via activation of GABA transaminase (vitamin B6-dependent) and stimulates presynaptic GABA release, broadly reducing neuronal excitability in key limbic and cortical circuits. This underpins its antihypoxic and neuroprotective effects in ischemia models.
Key Features & Specifications
Phenibut offers a pharmacologically distinctive GABAergic-gabapentinoid-dopaminergic profile relevant to anxiety, pain, and cognition research:
Chemical Analysis
| Property | Specification Reference Data |
|---|---|
| IUPAC Name | 4-amino-3-phenylbutanoic acid (free base) / 4-amino-3-phenylbutyric acid hydrochloride (HCl salt) |
| CAS Number | 1078-21-3 (free base); 3060-41-1 (HCl salt) |
| Molecular Formula | C10H13NO2 (free base); C10H14ClNO2 (HCl) |
| Molecular Weight | 179.22 g/mol (free base); 215.68 g/mol (HCl) |
| PubChem CID | 14113 |
| Synonyms | β-Phenyl-GABA, PhGABA, Fenibut, Phenigamma, Noofen |
| Form / Variation | 300 MG HCl Capsules — C-031 ($38.00) |
Storage, Safety, and Handling
Storage Protocol
Store capsules at controlled room temperature (15–25 °C), in a dry location, protected from light. The hydrochloride salt is hygroscopic; moisture exposure degrades product quality. Bulk powder should be stored in sealed, desiccated containers. Shelf life under proper conditions is typically 24–36 months.
Handling & Compliance
Handle with standard laboratory PPE. Phenibut is not scheduled as a controlled substance in the United States or EU, though regulatory status varies by jurisdiction and has been subject to review (ECDD report, 2023). Researchers should document potential CNS-depressant interactions and tolerance-sensitization effects in repeated-dose protocol designs.